Aroa is unlocking regenerative healing, accessability and affordabilityFind out more
Reinforced Bioscaffolds combine the best of biologics and synthetics to address the current shortcomings in surgical ventral hernia repair solutions. Read more about Reinforced Bioscaffolds on the TelaBio website.
Find out more
Our focus is delivering better healing, everyday, everywhere for everybody. We strive to make a meaningful impact for patients, surgeons and clinicians. We deliver high quality, simple to…Find out more
Auckland, NZ. Aroa Biosurgery a New Zealand-headquartered, emerging global leader for tissue regeneration products used in complex wounds and soft tissue repair, has announced the appointment of a highly experienced U.S. based executive, Brad Adams, to the new position of Vice President, Commercial.
Aroa Chief Executive Brian Ward welcomed the appointment of Mr Adams, who brings 20-years of experience in the strategic sales and marketing of medical devices within the United States medical system.
Auckland, NZ. Aroa Biosurgery, the Auckland-based privately held tissue-regeneration company, has this week presented positive outcomes of a new clinical study in Canada performed using its core wound product Endoform Natural®, which is being launched in the Canadian market along with Endoform Antimicrobial® in October 2019.
Auckland, NZ. Aroa Biosurgery has posted a modest profit for the FY18/19 year, a first for the Auckland-based, privately held tissue-regeneration company since its formation 10 years ago.
Chief Executive Brian Ward said the first-time push into profit would be welcome news for the company’s tight and supportive family of investors. It was achieved off the back of 118% revenue growth to $24.2 million